Frankfurt
12.09.25 | 15:46
0,055 Euro
0,00 % 0,000
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,053 | 0,079 | 22:33 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.09. | Ventripoint Diagnostics Ltd.: Ventripoint Announces Closing of First Tranche of Non-Brokered Convertible Debenture Unit Private Placement | 1 | TheNewswire | ||
| 27.08. | Ventripoint Diagnostics Ltd (2): Ventripoint arranges $5M financing of debenture units | 1 | Stockwatch | ||
| 26.08. | Ventripoint Diagnostics Ltd.: Ventripoint Announces Non-Brokered Convertible Debenture Units Private Placement and Share Issuance | 2 | TheNewswire | ||
| 19.08. | Ventripoint Diagnostics Ltd (2): Ventripoint appoints Brown as program director | 1 | Stockwatch | ||
| 18.08. | Ventripoint Diagnostics Ltd.: Ventripoint Diagnostics Appoints Thomas Brown as Director of Congenital Heart Defect Program | 1 | TheNewswire | ||
| VENTRIPOINT DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 15.08. | Ventripoint Diagnostics Ltd.: Ventripoint Diagnostics Launches Targeted Congenital Heart Defect Marketing Program, Setting Stage for Multi-Segment Growth | 1 | TheNewswire | ||
| 13.08. | CEO.CA Technologies Ltd.: CEO.CA's Inside the Boardroom: Cardiac MRI Alternative Gets FDA Nod - Ventripoint CEO on U.S. and China Sales Plans | 301 | Newsfile | Toronto, Ontario--(Newsfile Corp. - August 13, 2025) - CEO.CA ("CEO.CA"), the leading investor social network in junior resource and venture stocks, shares exclusive updates with CEOs of junior mining... ► Artikel lesen | |
| 29.07. | Ventripoint Diagnostics Ltd (2): Ventripoint receives purchase order from Lishman | 1 | Stockwatch | ||
| 28.07. | Ventripoint Diagnostics Ltd.: Lishman Global Places First Order for Ventripoint's VMS+ Technology | 1 | TheNewswire | ||
| 11.07. | Ventripoint Diagnostics Ltd (2): Ventripoint enters term sheet with Lishman for licence | 1 | Stockwatch | ||
| 11.07. | Ventripoint Diagnostics Ltd.: Ventripoint and Lishman Global Sign Non-binding Term Sheet Defining License for VMS+ Technology | 2 | TheNewswire | ||
| 11.07. | Ventripoint Diagnostics Ltd (2): Ventripoint Diagnostics 564,473 shares for debt | 1 | Stockwatch | ||
| 30.06. | Ventripoint Diagnostics Ltd (2): Ventripoint to settle debenture interest with shares | 2 | Stockwatch | ||
| 30.06. | Ventripoint Diagnostics Ltd.: Ventripoint to Issue Shares for Payment of Debenture Interest | 1 | TheNewswire | ||
| 18.06. | Ventripoint Diagnostics Ltd (2): Ventripoint hires Fournel for advisory services | 1 | Stockwatch | ||
| 17.06. | Ventripoint Diagnostics Ltd (2): Ventripoint Diagnostics grants options | 4 | Stockwatch | ||
| 17.06. | Ventripoint Diagnostics Ltd.: Ventripoint Issues Option Grants and Reports Exercise of Options | 2 | TheNewswire | ||
| 17.06. | Ventripoint Diagnostics Ltd.: Ventripoint Partners with Fournel Advisory | 2 | TheNewswire | ||
| 28.05. | Ventripoint Diagnostics Ltd.: Ventripoint to Exhibit at the 58th Annual Meeting of the Association for European Paediatric and Congenital Cardiology | 1 | TheNewswire | ||
| 30.04. | Ventripoint Diagnostics Ltd (2): Ventripoint appoints Gall to business advisory board | 1 | Stockwatch |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ATOSSA THERAPEUTICS | 0,700 | -0,57 % | Atossa Genetics stock rating reiterated by H.C. Wainwright on FDA meeting plans | ||
| TANDEM DIABETES | 10,900 | +0,09 % | Tandem Diabetes Care auf Morgan Stanley Konferenz: Strategische Wachstumspläne vorgestellt | ||
| VERU | 3,490 | -1,97 % | Veru Inc.: Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress | --Company reported positive efficacy and safety data from Phase 2b QUALITY study showing enobosarm added to semaglutide led to preservation of muscle, greater fat loss, and fewer gastrointestinal... ► Artikel lesen | |
| MOLINA HEALTHCARE | 155,20 | -3,33 % | Molina Healthcare-Aktie kann Vortagsniveau nicht halten (145,6140 €) | Im US-amerikanischen Wertpapierhandel liegt das Wertpapier von Molina Healthcare gegenwärtig im Minus. Das Wertpapier notiert aktuell bei 169,55 US-Dollar. Heute hat sich am US-amerikanischen Aktienmarkt... ► Artikel lesen | |
| CLOVER HEALTH INVESTMENTS | 2,556 | -4,31 % | Clover Health Investments, Corp.: Counterpart Health Launches Integrated Scribing, Supercharging Counterpart Assistant with Smarter, Seamless Scribing Built for Value-Based Care | ||
| COGNETIVITY NEUROSCIENCES | 0,015 | -100,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.06.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 02.06.2025Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.06.2025ISIN NameCA19243C1005 COGNETIVITY... ► Artikel lesen | |
| SOMNIGROUP INTERNATIONAL | 72,50 | -1,36 % | Insider Unloading: Cathy Gates Sells $522K Worth Of Somnigroup International Shares | ||
| SHL TELEMEDICINE | - | - | SHL TELEMEDICINE LTD - 6-K, Report of foreign issuer | ||
| SINTX TECHNOLOGIES | 4,350 | -4,40 % | SINTX Technologies, Inc.: SINTX Technologies Receives USPTO Notice of Allowance for Silicon Nitride Antipathogenic Platform Patent | Significant Development in the Estimated $30 Billion Global Infection-Prevention Market SALT LAKE CITY, Utah, Sept. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) ("SINTX"... ► Artikel lesen | |
| SEMLER SCIENTIFIC | 24,800 | +1,64 % | Aktionäre von Semler Scientific genehmigen Erhöhung der Stammaktien, lehnen Vorzugsaktien-Vorschlag ab | ||
| SMILEDIRECTCLUB | - | - | Align Technology Settles Antitrust Lawsuit Over SmileDirectClub Deal for $31.75 Million | ||
| RELEVIUM | 0,013 | -100,00 % | Relevium Technologies Inc.: Relevium Technologies to be delisted from NEX | ||
| NEURONETICS | 3,010 | +2,21 % | Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 47,620 | -0,79 % | Siemens Healthineers - kann ein möglicher Verkauf einer Problemsparte die Aktie beflügeln? | ||
| FRESENIUS | 46,540 | -1,19 % | Fresenius platziert Anleihen im Volumen von 1 Milliarde Euro | DJ Fresenius platziert Anleihen im Volumen von 1 Milliarde Euro
DOW JONES--Fresenius hat nach fast zweijähriger Abwesenheit vom Euro-Anleihemarkt zwei Anleihen im Gesamtvolumen von 1 Milliarde... ► Artikel lesen |
VENTRIPOINT DIAGNOSTICS LTD gehört der Branche Gesundheitswesen an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,055 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VENTRIPOINT DIAGNOSTICS LTD finden Sie auf Wallstreet Online.